Alport Syndrome clinical trials at University of California Health
2 research studies open to eligible people
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
open to eligible people ages 12 years and up
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.
at UCLA UCSF
Atrasentan in Patients With Proteinuric Glomerular Diseases
open to eligible people ages 18 years and up
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
at UCLA
Our lead scientists for Alport Syndrome research studies include Meyeon Park, MD Anjay Rastogi, MD.
Last updated: